Global Dermatological Therapeutics

Dermatological Therapeutics Comprehensive Study by Type (Anti-infectives , Corticosteroids, Anti Psoriasis, Anti-acne , Others), Application (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopecia, Others), Drug Type (Prescription-Based Drugs, Over-the-Counter Drugs), Route of Administration (Topical, Oral, Parenteral Administration), Drug Class (Anti-infectives, Corticosteroids, Calcineurin Inhibitors, Retinoids, Other) Players and Region - Global Market Outlook to 2030

Dermatological Therapeutics Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Dermatological Therapeutics
Dermatology is the science that is concerned with the diagnosis and treatment of diseases of the skin, hair and nails, which occurs due to range of things, like infections, heat, allergens, system disorders and medications. Primary common skin disorders are dermatitis and the atopic dermatitis is associate chronic condition that causes restless, inflamed skin. Most commonly it seems as patches on the face, neck, trunk or limbs. It tends to flare up sporadically so subside for a time. Dermatology diagnosis the normal and disorders, diseases, cancers, cosmetic and ageing conditions of the skin, fat, hair, nails and genital membranes, with the help of different investigations and therapies, including but not limited to dermatohistopathology, topical and systemic medications, dermatologic surgery and dermatologic cosmetic surgery, immunotherapy, laser therapy, radiotherapy and photodynamic therapy.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Dermatological Therapeutics market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

AbbVie Inc. (United States), Amgen Inc. (United States), Almirall SA (Spain), Bausch Health Companies Inc. (Canada), Galderma SA (Switzerland), GlaxoSmithKline PLC (United Kingdom), Bayer AG (Germany), Johnson & Johnson (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Mallinckrodt plc (United Kingdom), Mersana Therapeutics, Inc. (United States), Novavax, Inc. (United States) and Amarin Corporation plc (Ireland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Hoth Therapeutics, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Dermatological Therapeutics market by Type (Anti-infectives , Corticosteroids, Anti Psoriasis, Anti-acne  and Others), Application (Acne, Dermatitis, Psoriasis, Skin Cancer, Rosacea, Alopecia and Others) and Region.



On the basis of geography, the market of Dermatological Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug Type, the sub-segment i.e. Prescription-Based Drugs will boost the Dermatological Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Topical will boost the Dermatological Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Anti-infectives will boost the Dermatological Therapeutics market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising Demand for Rapid Diagnosis

Market Growth Drivers:
Increasing Incidence Of Skin Cancer And Other Skin Disorders and Growing Levels of Awareness-Related Disease Progression, Etiology

Challenges:
Lack of Professionals Doctors

Restraints:
Serious Side Effects for Some Classes of Therapeutic Drugs and Stringent Government Regulations on Dermatological Drugs

Opportunities:
Development of Innovative Products by Manufacturers

Market Leaders and their expansionary development strategies
On October 6, 2023, Galderma, a global leader in dermatology, announced the acquisition of Aclaris Therapeutics, a US-based biopharmaceutical company focused on rare skin diseases. This deal strengthens Galderma's portfolio in niche markets and provides access to promising late-stage pipeline assets.
On September 12, 2023, LEO Pharma and Galderma announced a research and development collaboration to identify and develop novel treatments for atopic dermatitis (eczema). This partnership combines LEO Pharma's expertise in immunology with Galderma's strength in dermatology to accelerate the development of innovative therapies.


Key Target Audience
Manufacturers of Dermatology Drug, Suppliers of Dermatology Drug, Wholesalers, Distributors and Retailers of Dermatology Drug, Pharmaceutical Industry, Regulatory Bodies and Governmental Bodies

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Anti-infectives 
  • Corticosteroids
  • Anti Psoriasis
  • Anti-acne 
  • Others
By Application
  • Acne
  • Dermatitis
  • Psoriasis
  • Skin Cancer
  • Rosacea
  • Alopecia
  • Others
By Drug Type
  • Prescription-Based Drugs
  • Over-the-Counter Drugs

By Route of Administration
  • Topical
  • Oral
  • Parenteral Administration

By Drug Class
  • Anti-infectives
  • Corticosteroids
  • Calcineurin Inhibitors
  • Retinoids
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence Of Skin Cancer And Other Skin Disorders
      • 3.2.2. Growing Levels of Awareness-Related Disease Progression, Etiology
    • 3.3. Market Challenges
      • 3.3.1. Lack of Professionals Doctors
    • 3.4. Market Trends
      • 3.4.1. Rising Demand for Rapid Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dermatological Therapeutics, by Type, Application, Drug Type, Route of Administration, Drug Class and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Dermatological Therapeutics (Value)
      • 5.2.1. Global Dermatological Therapeutics by: Type (Value)
        • 5.2.1.1. Anti-infectives 
        • 5.2.1.2. Corticosteroids
        • 5.2.1.3. Anti Psoriasis
        • 5.2.1.4. Anti-acne 
        • 5.2.1.5. Others
      • 5.2.2. Global Dermatological Therapeutics by: Application (Value)
        • 5.2.2.1. Acne
        • 5.2.2.2. Dermatitis
        • 5.2.2.3. Psoriasis
        • 5.2.2.4. Skin Cancer
        • 5.2.2.5. Rosacea
        • 5.2.2.6. Alopecia
        • 5.2.2.7. Others
      • 5.2.3. Global Dermatological Therapeutics by: Drug Type (Value)
        • 5.2.3.1. Prescription-Based Drugs
        • 5.2.3.2. Over-the-Counter Drugs
      • 5.2.4. Global Dermatological Therapeutics by: Route of Administration (Value)
        • 5.2.4.1. Topical
        • 5.2.4.2. Oral
        • 5.2.4.3. Parenteral Administration
      • 5.2.5. Global Dermatological Therapeutics by: Drug Class (Value)
        • 5.2.5.1. Anti-infectives
        • 5.2.5.2. Corticosteroids
        • 5.2.5.3. Calcineurin Inhibitors
        • 5.2.5.4. Retinoids
        • 5.2.5.5. Other
      • 5.2.6. Global Dermatological Therapeutics Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Dermatological Therapeutics (Price)
      • 5.3.1. Global Dermatological Therapeutics by: Type (Price)
  • 6. Dermatological Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. AbbVie Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Amgen Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Almirall SA (Spain)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health Companies Inc. (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Galderma SA (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bayer AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Johnson & Johnson (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novartis International AG (Switzerland)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Pfizer Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Mallinckrodt plc (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Mersana Therapeutics, Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Novavax, Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Amarin Corporation plc (Ireland)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Dermatological Therapeutics Sale, by Type, Application, Drug Type, Route of Administration, Drug Class and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Dermatological Therapeutics (Value)
      • 7.2.1. Global Dermatological Therapeutics by: Type (Value)
        • 7.2.1.1. Anti-infectives 
        • 7.2.1.2. Corticosteroids
        • 7.2.1.3. Anti Psoriasis
        • 7.2.1.4. Anti-acne 
        • 7.2.1.5. Others
      • 7.2.2. Global Dermatological Therapeutics by: Application (Value)
        • 7.2.2.1. Acne
        • 7.2.2.2. Dermatitis
        • 7.2.2.3. Psoriasis
        • 7.2.2.4. Skin Cancer
        • 7.2.2.5. Rosacea
        • 7.2.2.6. Alopecia
        • 7.2.2.7. Others
      • 7.2.3. Global Dermatological Therapeutics by: Drug Type (Value)
        • 7.2.3.1. Prescription-Based Drugs
        • 7.2.3.2. Over-the-Counter Drugs
      • 7.2.4. Global Dermatological Therapeutics by: Route of Administration (Value)
        • 7.2.4.1. Topical
        • 7.2.4.2. Oral
        • 7.2.4.3. Parenteral Administration
      • 7.2.5. Global Dermatological Therapeutics by: Drug Class (Value)
        • 7.2.5.1. Anti-infectives
        • 7.2.5.2. Corticosteroids
        • 7.2.5.3. Calcineurin Inhibitors
        • 7.2.5.4. Retinoids
        • 7.2.5.5. Other
      • 7.2.6. Global Dermatological Therapeutics Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Dermatological Therapeutics (Price)
      • 7.3.1. Global Dermatological Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dermatological Therapeutics: by Type(USD Million)
  • Table 2. Dermatological Therapeutics Anti-infectives  , by Region USD Million (2018-2023)
  • Table 3. Dermatological Therapeutics Corticosteroids , by Region USD Million (2018-2023)
  • Table 4. Dermatological Therapeutics Anti Psoriasis , by Region USD Million (2018-2023)
  • Table 5. Dermatological Therapeutics Anti-acne  , by Region USD Million (2018-2023)
  • Table 6. Dermatological Therapeutics Others , by Region USD Million (2018-2023)
  • Table 7. Dermatological Therapeutics: by Application(USD Million)
  • Table 8. Dermatological Therapeutics Acne , by Region USD Million (2018-2023)
  • Table 9. Dermatological Therapeutics Dermatitis , by Region USD Million (2018-2023)
  • Table 10. Dermatological Therapeutics Psoriasis , by Region USD Million (2018-2023)
  • Table 11. Dermatological Therapeutics Skin Cancer , by Region USD Million (2018-2023)
  • Table 12. Dermatological Therapeutics Rosacea , by Region USD Million (2018-2023)
  • Table 13. Dermatological Therapeutics Alopecia , by Region USD Million (2018-2023)
  • Table 14. Dermatological Therapeutics Others , by Region USD Million (2018-2023)
  • Table 15. Dermatological Therapeutics: by Drug Type(USD Million)
  • Table 16. Dermatological Therapeutics Prescription-Based Drugs , by Region USD Million (2018-2023)
  • Table 17. Dermatological Therapeutics Over-the-Counter Drugs , by Region USD Million (2018-2023)
  • Table 18. Dermatological Therapeutics: by Route of Administration(USD Million)
  • Table 19. Dermatological Therapeutics Topical , by Region USD Million (2018-2023)
  • Table 20. Dermatological Therapeutics Oral , by Region USD Million (2018-2023)
  • Table 21. Dermatological Therapeutics Parenteral Administration , by Region USD Million (2018-2023)
  • Table 22. Dermatological Therapeutics: by Drug Class(USD Million)
  • Table 23. Dermatological Therapeutics Anti-infectives , by Region USD Million (2018-2023)
  • Table 24. Dermatological Therapeutics Corticosteroids , by Region USD Million (2018-2023)
  • Table 25. Dermatological Therapeutics Calcineurin Inhibitors , by Region USD Million (2018-2023)
  • Table 26. Dermatological Therapeutics Retinoids , by Region USD Million (2018-2023)
  • Table 27. Dermatological Therapeutics Other , by Region USD Million (2018-2023)
  • Table 28. South America Dermatological Therapeutics, by Country USD Million (2018-2023)
  • Table 29. South America Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 30. South America Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 31. South America Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 32. South America Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 33. South America Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 34. Brazil Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 35. Brazil Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 36. Brazil Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 37. Brazil Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 38. Brazil Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 39. Argentina Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 40. Argentina Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 41. Argentina Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 42. Argentina Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 43. Argentina Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 44. Rest of South America Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 45. Rest of South America Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 46. Rest of South America Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 47. Rest of South America Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 48. Rest of South America Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 49. Asia Pacific Dermatological Therapeutics, by Country USD Million (2018-2023)
  • Table 50. Asia Pacific Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 51. Asia Pacific Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 52. Asia Pacific Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 53. Asia Pacific Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 54. Asia Pacific Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 55. China Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 56. China Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 57. China Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 58. China Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 59. China Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 60. Japan Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 61. Japan Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 62. Japan Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 63. Japan Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 64. Japan Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 65. India Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 66. India Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 67. India Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 68. India Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 69. India Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 70. South Korea Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 71. South Korea Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 72. South Korea Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 73. South Korea Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 74. South Korea Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 75. Taiwan Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 76. Taiwan Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 77. Taiwan Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 78. Taiwan Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 79. Taiwan Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 80. Australia Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 81. Australia Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 82. Australia Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 83. Australia Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 84. Australia Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 87. Rest of Asia-Pacific Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 88. Rest of Asia-Pacific Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 89. Rest of Asia-Pacific Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 90. Europe Dermatological Therapeutics, by Country USD Million (2018-2023)
  • Table 91. Europe Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 92. Europe Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 93. Europe Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 94. Europe Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 95. Europe Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 96. Germany Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 97. Germany Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 98. Germany Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 99. Germany Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 100. Germany Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 101. France Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 102. France Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 103. France Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 104. France Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 105. France Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 106. Italy Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 107. Italy Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 108. Italy Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 109. Italy Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 110. Italy Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 111. United Kingdom Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 112. United Kingdom Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 113. United Kingdom Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 114. United Kingdom Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 115. United Kingdom Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 116. Netherlands Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 117. Netherlands Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 118. Netherlands Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 119. Netherlands Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 120. Netherlands Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 121. Rest of Europe Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 122. Rest of Europe Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 123. Rest of Europe Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 124. Rest of Europe Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 125. Rest of Europe Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 126. MEA Dermatological Therapeutics, by Country USD Million (2018-2023)
  • Table 127. MEA Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 128. MEA Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 129. MEA Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 130. MEA Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 131. MEA Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 132. Middle East Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 133. Middle East Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 134. Middle East Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 135. Middle East Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 136. Middle East Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 137. Africa Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 138. Africa Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 139. Africa Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 140. Africa Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 141. Africa Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 142. North America Dermatological Therapeutics, by Country USD Million (2018-2023)
  • Table 143. North America Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 144. North America Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 145. North America Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 146. North America Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 147. North America Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 148. United States Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 149. United States Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 150. United States Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 151. United States Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 152. United States Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 153. Canada Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 154. Canada Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 155. Canada Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 156. Canada Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 157. Canada Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 158. Mexico Dermatological Therapeutics, by Type USD Million (2018-2023)
  • Table 159. Mexico Dermatological Therapeutics, by Application USD Million (2018-2023)
  • Table 160. Mexico Dermatological Therapeutics, by Drug Type USD Million (2018-2023)
  • Table 161. Mexico Dermatological Therapeutics, by Route of Administration USD Million (2018-2023)
  • Table 162. Mexico Dermatological Therapeutics, by Drug Class USD Million (2018-2023)
  • Table 163. Dermatological Therapeutics: by Type(USD/Units)
  • Table 164. Company Basic Information, Sales Area and Its Competitors
  • Table 165. Company Basic Information, Sales Area and Its Competitors
  • Table 166. Company Basic Information, Sales Area and Its Competitors
  • Table 167. Company Basic Information, Sales Area and Its Competitors
  • Table 168. Company Basic Information, Sales Area and Its Competitors
  • Table 169. Company Basic Information, Sales Area and Its Competitors
  • Table 170. Company Basic Information, Sales Area and Its Competitors
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Dermatological Therapeutics: by Type(USD Million)
  • Table 179. Dermatological Therapeutics Anti-infectives  , by Region USD Million (2025-2030)
  • Table 180. Dermatological Therapeutics Corticosteroids , by Region USD Million (2025-2030)
  • Table 181. Dermatological Therapeutics Anti Psoriasis , by Region USD Million (2025-2030)
  • Table 182. Dermatological Therapeutics Anti-acne  , by Region USD Million (2025-2030)
  • Table 183. Dermatological Therapeutics Others , by Region USD Million (2025-2030)
  • Table 184. Dermatological Therapeutics: by Application(USD Million)
  • Table 185. Dermatological Therapeutics Acne , by Region USD Million (2025-2030)
  • Table 186. Dermatological Therapeutics Dermatitis , by Region USD Million (2025-2030)
  • Table 187. Dermatological Therapeutics Psoriasis , by Region USD Million (2025-2030)
  • Table 188. Dermatological Therapeutics Skin Cancer , by Region USD Million (2025-2030)
  • Table 189. Dermatological Therapeutics Rosacea , by Region USD Million (2025-2030)
  • Table 190. Dermatological Therapeutics Alopecia , by Region USD Million (2025-2030)
  • Table 191. Dermatological Therapeutics Others , by Region USD Million (2025-2030)
  • Table 192. Dermatological Therapeutics: by Drug Type(USD Million)
  • Table 193. Dermatological Therapeutics Prescription-Based Drugs , by Region USD Million (2025-2030)
  • Table 194. Dermatological Therapeutics Over-the-Counter Drugs , by Region USD Million (2025-2030)
  • Table 195. Dermatological Therapeutics: by Route of Administration(USD Million)
  • Table 196. Dermatological Therapeutics Topical , by Region USD Million (2025-2030)
  • Table 197. Dermatological Therapeutics Oral , by Region USD Million (2025-2030)
  • Table 198. Dermatological Therapeutics Parenteral Administration , by Region USD Million (2025-2030)
  • Table 199. Dermatological Therapeutics: by Drug Class(USD Million)
  • Table 200. Dermatological Therapeutics Anti-infectives , by Region USD Million (2025-2030)
  • Table 201. Dermatological Therapeutics Corticosteroids , by Region USD Million (2025-2030)
  • Table 202. Dermatological Therapeutics Calcineurin Inhibitors , by Region USD Million (2025-2030)
  • Table 203. Dermatological Therapeutics Retinoids , by Region USD Million (2025-2030)
  • Table 204. Dermatological Therapeutics Other , by Region USD Million (2025-2030)
  • Table 205. South America Dermatological Therapeutics, by Country USD Million (2025-2030)
  • Table 206. South America Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 207. South America Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 208. South America Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 209. South America Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 210. South America Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 211. Brazil Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 212. Brazil Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 213. Brazil Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 214. Brazil Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 215. Brazil Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 216. Argentina Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 217. Argentina Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 218. Argentina Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 219. Argentina Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 220. Argentina Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 221. Rest of South America Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 222. Rest of South America Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 223. Rest of South America Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 224. Rest of South America Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 225. Rest of South America Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 226. Asia Pacific Dermatological Therapeutics, by Country USD Million (2025-2030)
  • Table 227. Asia Pacific Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 228. Asia Pacific Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 229. Asia Pacific Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 230. Asia Pacific Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 231. Asia Pacific Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 232. China Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 233. China Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 234. China Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 235. China Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 236. China Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 237. Japan Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 238. Japan Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 239. Japan Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 240. Japan Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 241. Japan Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 242. India Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 243. India Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 244. India Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 245. India Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 246. India Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 247. South Korea Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 248. South Korea Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 249. South Korea Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 250. South Korea Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 251. South Korea Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 252. Taiwan Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 253. Taiwan Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 254. Taiwan Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 255. Taiwan Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 256. Taiwan Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 257. Australia Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 258. Australia Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 259. Australia Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 260. Australia Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 261. Australia Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 262. Rest of Asia-Pacific Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 263. Rest of Asia-Pacific Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 264. Rest of Asia-Pacific Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 265. Rest of Asia-Pacific Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 266. Rest of Asia-Pacific Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 267. Europe Dermatological Therapeutics, by Country USD Million (2025-2030)
  • Table 268. Europe Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 269. Europe Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 270. Europe Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 271. Europe Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 272. Europe Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 273. Germany Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 274. Germany Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 275. Germany Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 276. Germany Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 277. Germany Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 278. France Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 279. France Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 280. France Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 281. France Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 282. France Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 283. Italy Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 284. Italy Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 285. Italy Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 286. Italy Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 287. Italy Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 288. United Kingdom Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 289. United Kingdom Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 290. United Kingdom Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 291. United Kingdom Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 292. United Kingdom Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 293. Netherlands Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 294. Netherlands Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 295. Netherlands Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 296. Netherlands Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 297. Netherlands Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 298. Rest of Europe Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 299. Rest of Europe Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 300. Rest of Europe Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 301. Rest of Europe Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 302. Rest of Europe Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 303. MEA Dermatological Therapeutics, by Country USD Million (2025-2030)
  • Table 304. MEA Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 305. MEA Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 306. MEA Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 307. MEA Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 308. MEA Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 309. Middle East Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 310. Middle East Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 311. Middle East Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 312. Middle East Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 313. Middle East Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 314. Africa Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 315. Africa Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 316. Africa Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 317. Africa Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 318. Africa Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 319. North America Dermatological Therapeutics, by Country USD Million (2025-2030)
  • Table 320. North America Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 321. North America Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 322. North America Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 323. North America Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 324. North America Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 325. United States Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 326. United States Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 327. United States Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 328. United States Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 329. United States Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 330. Canada Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 331. Canada Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 332. Canada Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 333. Canada Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 334. Canada Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 335. Mexico Dermatological Therapeutics, by Type USD Million (2025-2030)
  • Table 336. Mexico Dermatological Therapeutics, by Application USD Million (2025-2030)
  • Table 337. Mexico Dermatological Therapeutics, by Drug Type USD Million (2025-2030)
  • Table 338. Mexico Dermatological Therapeutics, by Route of Administration USD Million (2025-2030)
  • Table 339. Mexico Dermatological Therapeutics, by Drug Class USD Million (2025-2030)
  • Table 340. Dermatological Therapeutics: by Type(USD/Units)
  • Table 341. Research Programs/Design for This Report
  • Table 342. Key Data Information from Secondary Sources
  • Table 343. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dermatological Therapeutics: by Type USD Million (2018-2023)
  • Figure 5. Global Dermatological Therapeutics: by Application USD Million (2018-2023)
  • Figure 6. Global Dermatological Therapeutics: by Drug Type USD Million (2018-2023)
  • Figure 7. Global Dermatological Therapeutics: by Route of Administration USD Million (2018-2023)
  • Figure 8. Global Dermatological Therapeutics: by Drug Class USD Million (2018-2023)
  • Figure 9. South America Dermatological Therapeutics Share (%), by Country
  • Figure 10. Asia Pacific Dermatological Therapeutics Share (%), by Country
  • Figure 11. Europe Dermatological Therapeutics Share (%), by Country
  • Figure 12. MEA Dermatological Therapeutics Share (%), by Country
  • Figure 13. North America Dermatological Therapeutics Share (%), by Country
  • Figure 14. Global Dermatological Therapeutics: by Type USD/Units (2018-2023)
  • Figure 15. Global Dermatological Therapeutics share by Players 2023 (%)
  • Figure 16. Global Dermatological Therapeutics share by Players (Top 3) 2023(%)
  • Figure 17. Global Dermatological Therapeutics share by Players (Top 5) 2023(%)
  • Figure 18. BCG Matrix for key Companies
  • Figure 19. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. AbbVie Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Almirall SA (Spain) Revenue, Net Income and Gross profit
  • Figure 24. Almirall SA (Spain) Revenue: by Geography 2023
  • Figure 25. Bausch Health Companies Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Bausch Health Companies Inc. (Canada) Revenue: by Geography 2023
  • Figure 27. Galderma SA (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Galderma SA (Switzerland) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 35. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 37. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 39. Mallinckrodt plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. Mallinckrodt plc (United Kingdom) Revenue: by Geography 2023
  • Figure 41. Mersana Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Mersana Therapeutics, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Novavax, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Novavax, Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Amarin Corporation plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 46. Amarin Corporation plc (Ireland) Revenue: by Geography 2023
  • Figure 47. Global Dermatological Therapeutics: by Type USD Million (2025-2030)
  • Figure 48. Global Dermatological Therapeutics: by Application USD Million (2025-2030)
  • Figure 49. Global Dermatological Therapeutics: by Drug Type USD Million (2025-2030)
  • Figure 50. Global Dermatological Therapeutics: by Route of Administration USD Million (2025-2030)
  • Figure 51. Global Dermatological Therapeutics: by Drug Class USD Million (2025-2030)
  • Figure 52. South America Dermatological Therapeutics Share (%), by Country
  • Figure 53. Asia Pacific Dermatological Therapeutics Share (%), by Country
  • Figure 54. Europe Dermatological Therapeutics Share (%), by Country
  • Figure 55. MEA Dermatological Therapeutics Share (%), by Country
  • Figure 56. North America Dermatological Therapeutics Share (%), by Country
  • Figure 57. Global Dermatological Therapeutics: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • AbbVie Inc. (United States)
  • Amgen Inc. (United States)
  • Almirall SA (Spain)
  • Bausch Health Companies Inc. (Canada)
  • Galderma SA (Switzerland)
  • GlaxoSmithKline PLC (United Kingdom)
  • Bayer AG (Germany)
  • Johnson & Johnson (United States)
  • Novartis International AG (Switzerland)
  • Pfizer Inc. (United States)
  • Mallinckrodt plc (United Kingdom)
  • Mersana Therapeutics, Inc. (United States)
  • Novavax, Inc. (United States)
  • Amarin Corporation plc (Ireland)
Additional players considered in the study are as follows:
Hoth Therapeutics, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 221 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dermatological Therapeutics Quantitative research analysis
Global Dermatological Therapeutics Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as AbbVie Inc. (United States), Amgen Inc. (United States), Almirall SA (Spain), Bausch Health Companies Inc. (Canada), Galderma SA (Switzerland), GlaxoSmithKline PLC (United Kingdom), Bayer AG (Germany), Johnson & Johnson (United States), Novartis International AG (Switzerland), Pfizer Inc. (United States), Mallinckrodt plc (United Kingdom), Mersana Therapeutics, Inc. (United States), Novavax, Inc. (United States) and Amarin Corporation plc (Ireland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising Demand for Rapid Diagnosis" is seen as one of major influencing trends for Dermatological Therapeutics Market during projected period 2023-2030.
The Dermatological Therapeutics market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Dermatological Therapeutics Report?

Have a Query? Click Here

Other Related Reports

Thyroid Cancer Treatment Comprehensive Study by Type (Surgery, Iodine Therapy, External Radiotherapy, Thyroxin Treatment, Chemotherapy, Drugs), Application (Hospitals, Oncology centers, Hospital Phar...
$ 3650
Urinary Tract Cancer Comprehensive Study by Type (Urothelial Carcinoma, Squamous Cell Carcinoma, Adenocarcinoma, Others), Diagnosis Technique (Cytoscopy, Urine Analyses, Biopsy, Imaging Test (Compute...
$ 3750
Mesenchymal Stem Cells Comprehensive Study by Type (MSC-BM, MSC-UC, MSC-AT, Others), Application (Cell Differentiation and Gene Regulation, Gene Therapy and Transplantation, Cell-based Screening Assa...
$ 3500
Retinoblastoma Treatment Comprehensive Study by Type (Alkylating Agents, Antimetabolites, Microtubule Inhibitors, Cytotoxic Antibiotics, Topoisomerase Inhibitors), Application (Intraocular Retinoblas...
$ 3750
Orthokeratology Comprehensive Study by Type (Myopia, Hyperopia, Astigmatism, Presbyopia), Application (Ambulatory services, Hospitals, Clinics) Players and Region - Global Market Outlook to 2030
$ 3500
Orthopedic Prosthetics Comprehensive Study by Type (Upper Extremity Prosthetics (Hand Prosthetics, Elbow Prosthetics, Shoulder Prosthetics), Lower Extremity Prosthetics (Foot & Ankle Prosthetics, Kne...
$ 3750